NASDAQ: RNAZ
Transcode Therapeutics Inc Stock Ownership - Who owns Transcode Therapeutics?

Insider buying vs selling

Have Transcode Therapeutics Inc insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when RNAZ insiders and whales buy or sell their stock.

RNAZ Shareholders

What type of owners hold Transcode Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Anna Moore9.17%1,552,785$2.62MInsider
Zdravka Medarova9.17%1,552,785$2.62MInsider
Defj LLC1.77%300,040$507.07kInsider
Robert Michael Dudley1.06%180,262$304.64kInsider
Philippe Calais0.75%127,377$215.27kInsider
Thomas A. Fitzgerald0.33%56,318$95.18kInsider
Yorkvi0.00%20$33.80Institution
Yorkville Advisors Global LP0.00%19$32.11Institution
Vangrd0.00%7$11.83Institution
Vanguard Capital Management LLC0.00%6$10.14Institution

1 of 3

RNAZ vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RNAZ0.00%22.26%
ESLA0.01%68.68%Net BuyingNet Buying
IGC0.01%24.95%Net BuyingNet Buying
QNCX0.00%100.00%Net Selling
CVM0.01%52.55%Net BuyingNet Buying

Transcode Therapeutics Stock Ownership FAQ

Who owns Transcode Therapeutics?

Transcode Therapeutics (NASDAQ: RNAZ) is owned by 0.00% institutional shareholders, 22.26% Transcode Therapeutics insiders, and 77.74% retail investors. Anna Moore is the largest individual Transcode Therapeutics shareholder, owning 1.55M shares representing 9.17% of the company. Anna Moore's Transcode Therapeutics shares are currently valued at $2.56M.

If you're new to stock investing, here's how to buy Transcode Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.